ITI announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589 (‘589 Patent) issued on November 22, 2016, entitled “Chimeric Vaccines.” The issuance of the ‘589 Patent extends ITI’s foundational intellectual property portfolio covering specific LAMP vaccine constructs exclusively in-licensed from Johns Hopkins University. As part of license agreement with Astellas, ITI provided Astellas with exclusive rights to the ‘589 Patent family in defined fields which includes allergies. The issued claims of the ’589 Patent are directed to the DNA LAMP-Vax vaccines that are currently being tested in Astellas’ human clinical trials.
Immunomic-Therapeutics-Announces-Expansion-IP-Portfolio